Biogen's hemophilia A drug Eloctate OK'd in Canada
This article was originally published in Scrip
Executive Summary
Biogen Idec has won approval in Canada to market Eloctate (antihemophilic factor, recombinant BDD, Fc fusion protein) as a therapy to control and prevent bleeding episodes and as a routine prophylaxis in adults and children 12 years or older with hemophilia A, which affects about 142,000 people worldwide, including nearly 2,500 in Canada.